143 results
Page 7 of 8
DRS
rx59lj3
18 Dec 20
Draft registration statement
12:00am
6-K
EX-99.1
f0o0ft
17 Dec 20
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
6:15am
6-K
o0na8lnix tsr
9 Dec 20
Current report (foreign)
4:23pm
6-K
EX-99.1
f672n sogdbm9l5
9 Dec 20
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
6:30am
6-K
EX-99.1
qc1jn
8 Dec 20
Amryt Announces $40m Private Placement with Leading Biotech Investors
6:05am
6-K
EX-99.1
msu0edvn 4a7y421
5 Nov 20
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
7:55am
6-K
EX-99.1
od8mys
29 Oct 20
Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® In Epidermolysis Bullosa
8:00am
6-K
EX-99.1
gp8vre
19 Oct 20
Current report (foreign)
8:00am
6-K
EX-99.1
amm3n
15 Sep 20
Current report (foreign)
8:31am
6-K
EX-99.1
y7t methmy
9 Sep 20
Amryt Announces Positive Top Line Results from Pivotal Phase 3 “Ease” Trial of Filsuvez(r) In Epidermolysis Bullosa
8:23am
6-K
EX-99.1
zaal49p fv06dvikiigu
11 Aug 20
Notification of Cancellation of Admission to Euronext Growth
10:04am
6-K
EX-99.1
sr86w1h mj4q7owd
6 Aug 20
Amryt Announces Q2 2020 Results and Issues Positive Revenue Guidance for Fy 2020
9:43am
6-K
EX-99.1
l1ctbx20a9ag 8b8
10 Jul 20
Current report (foreign)
9:46am
424B4
wp6lt
8 Jul 20
Prospectus supplement with pricing info
4:05pm
F-1/A
2bu0504bdz9lsrcvh
6 Jul 20
Registration statement (foreign) (amended)
5:28pm
F-1
EX-2.1
7jk aupv54pfprc6
23 Jun 20
Registration statement (foreign)
5:21pm
F-1
EX-10.2
h4icnx6ranr93atmm8tb
23 Jun 20
Registration statement (foreign)
5:21pm
F-1
EX-10.5
t87q0a8gzqm wn9
23 Jun 20
Registration statement (foreign)
5:21pm
F-1
x57y2g j6mgwtkum110i
23 Jun 20
Registration statement (foreign)
5:21pm
DRS/A
8iui8nef ml
29 May 20
Draft registration statement (amended)
12:00am